Singapore markets closed

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
29.00+0.17 (+0.59%)
At close: 01:00PM EST
29.00 0.00 (0.00%)
After hours: 01:01PM EST

Agios Pharmaceuticals, Inc.

88 Sidney Street
2nd Floor
Cambridge, MA 02139-4169
United States
617 649 8600
https://www.agios.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees390

Key executives

NameTitlePayExercisedYear born
Dr. Bruce D. Car DACVP, Ph.D.Consultant776.12kN/A1961
Dr. Sarah Gheuens M.D., Ph.D.Chief Medical Officer and Head of R&D1.57M72.32k1980
Ms. Richa PoddarChief Commercial Officer624.08kN/A1982
Mr. Brian M. Goff M.B.A.CEO & DirectorN/AN/A1969
Dr. Lewis Clayton Cantley Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1946
Dr. Craig B. Thompson M.D.Co-Founder & Chairman of Scientific Advisory BoardN/AN/A1953
Dr. Shin-San Su Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1956
Ms. Cecilia JonesChief Financial OfficerN/AN/A1975
Mr. T. J. Washburn Jr.Principal Accounting OfficerN/AN/A1981
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Agios Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 November 2022 is 5. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.